Richard Burr: “We cannot wait until a threat is upon us to respond.”

What does it mean for a small company when FDA misses these goals, and what does it mean to patients?

I oppose Ms. Kotagal's nomination and urge my colleagues to do the same.

I was surprised and frustrated to hear that these funds were overwhelmingly repurposed from within ASPR, including the stockpile.

The faster, more predictable, and more accountable the programs are, the more patients stand to benefit from lifesaving, innovative drugs and devices.